The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School: Prostatic Neoplasms trials

The registry lists 24 Prostatic Neoplasms studies with The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School as lead sponsor. 11 are open to participants now and 0 have results posted.

Phase 2 11Phase 4 1No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ipsilateral Versus Bilateral Systematic Biopsy Combined With MRI/Ultrasound Cognitive Fusion Targeted Biopsy for Prostate Cancer DiagnosisRecruitingNCT07795723Not applicable
• Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical ProstatectomyRecruitingNCT07711314Phase 2
• 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical TrialNot yet recruitingNCT07677566Phase 4
• Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPCRecruitingNCT06992232Phase 2
• Diagnostic Value of MRI-targeted Plus Index-lesion-ipsilaterally Systematic Biopsy for Biopsy-naive Men At Risk of Prostate CancerRecruitingNCT06584279
• Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate CancerRecruitingNCT06305832Phase 2
• Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)Not yet recruitingNCT05778097Phase 2
• Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate CancerRecruitingNCT05753566Phase 2
• The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate CancerRecruitingNCT05461261Phase 2
• Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerRecruitingNCT05406999Phase 2
• Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate CancerRecruitingNCT05249712Phase 2
• Observing the Real-world Non-interventional Study of Abiraterone Acetate Tablets (II) in Treating Chinese Patients With Metastatic Prostate CancerActive, not recruitingNCT07721532
• Clinical Validation of the Prognostic Value of the PrTS on Prostate Cancer PatientsStatus unknownNCT05248282
• The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate CancerCompletedNCT04992026Phase 2
• Optimization of the Core Number and Location for Targeted Prostate BiopsyStatus unknownNCT04983706Not applicable
• MRI-Ultrasound Fusion or Cognitive Registration in MR-targeted Prostate BiopsyStatus unknownNCT04953351Not applicable
• SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate CancerCompletedNCT04676607Phase 2
• Effectiveness of 68Ga-PSMA PET/MRI for Improving the Detection of csPCa in Lesions With PI-RADS Score 3Status unknownNCT04573179
• A Prospective Study Of Free-Hand Transperineal Image Fusion Targeted Biopsies Under Local AnesthesiaCompletedNCT04376008Not applicable
• Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate CancerStatus unknownNCT04356430Phase 2
• Combined Prostate-specific Antigen, Multi-parametric MRI and Targeted Prostate Biopsy for Prostate Cancer ScreeningStatus unknownNCT04322045Not applicable
• Screening for Prostate Cancer Among Those Prostate-specific Antigen Value Between 2.5 and 4.0 ng/mLStatus unknownNCT04317625Not applicable
• Unfavorable MRI But Favorable 68Ga-PSMA PET/MRI for Primary Prostate Cancer DetectionStatus unknownNCT04124107Not applicable
• Targeted Biopsy or Standard Biopsy for Clinical Significant Prostate Cancer DetectionStatus unknownNCT03572946Not applicable